# Phase H-1 FULL-4-of-5 — Specific Results & Implications

**Date:** 2026-05-01
**Author:** Replit Agent (DPES autonomous mode), Brandon Charles Emerick
**Status:** Companion brief to `papers/AGENT_LOCKED_PREDICTIONS_2026-04-30.md` §8.7 / §8.7.a
**Editing rule:** This brief may be revised; numerical claims are pinned to the §8.7 frozen verdict.

---

## 1. Numbers, in one paragraph

The Phase H-1 FULL-4-of-5 simulator run with Brandon's R_intra_em substituted at 0.7001 (mean of mito_snp_score=0.9468, telomere_proxy=0.4167, cpg_promoter_density=0.4757, Oura overnight HRV-norm=0.7729, Oura sleep efficiency 7-day=0.8886) produced:

- **dev = 4.8488** (sum of |TI_predicted/Empirical − 1.0| across 12 reference cases)
- **Direction:** strictly LESS than §8.6 (4.9285) by **−0.0797**
- **Shift vs §8.4 passthrough (4.7719):** **+0.0769**
- **Mean Amp_TI:** ×1.1001
- **All three §10.4 pre-registered criteria HIT.**

---

## 2. What this proves

### 2.1 The simulator is monotonic in R_intra_em

Higher R_intra_em → higher amplification → smaller deviation from empirical reference cases. This monotonicity now holds end-to-end with **80% real input** (4 of 5 components from real data: 23andMe DNA + Oura biometrics; only the 5th — daytime HRV — is substituted by Oura overnight HRV).

The 4-decimal-place reproduction of the architect's r=0.7 deterministic sweep means there is no off-by-one, no silent floating-point drift, no parser bug in the chip-handling path. The pipeline is **architecturally sound**.

### 2.2 The 23andMe parser handles haploid calls correctly

The bug fix (single-letter MT/Y/male-X calls treated as homozygous instead of "non-callable") was **necessary, not cosmetic**. Without it, mito_snp_score would have collapsed from 0.9468 to ~0.0, R_intra_em would have dropped from 0.7001 to ~0.512, and the §10.4 verdict would have failed the upper band edge.

This bug fix transfers to **every future R_intra_em derivation** for any subject submitting a 23andMe v5 file. It is the most generalizable engineering output of this session.

### 2.3 The pipeline is ready for Phase B (weight learning)

The infrastructure now in place:
- 5-component R_intra_em decomposition (4 real + 1 substitute)
- Override hook in `compute_lcc_amplifier()` and `DivinationAmplifiedSimulator`
- Hard-fail drift detection (post §8.7.a)
- Reproducible per-subject scoring at $0 from existing 23andMe + Oura accounts

…is the **minimum** infrastructure needed to begin fitting w_em weights. Phase B can begin as soon as we have either (a) multi-time-point data per subject (we now have ≥30 days of Oura) or (b) multi-subject data.

---

## 3. What this does NOT prove (asymmetric-standards #69)

**One falsification > four confirmations. Each "NOT" below is a structural limit on what the §8.7 verdict can claim.**

### 3.1 NOT a Bayesian update on URB #826

The §10.4 prediction was a **deterministic-architectural** pre-registration: "if our math is right, the simulator will reproduce r=0.7 sweep within 4 decimals." That is a calibration test of the simulator, not a probabilistic test of the biophoton/EM-DNA hypothesis. Confirming a deterministic reproduction does not raise the posterior probability of URB #826 being true; it raises the posterior probability that the simulator is implemented correctly.

### 3.2 NOT validation of the proxies as constructs

- `mito_snp_score` measures **chip call quality and homoplasmy structure**, not mitochondrial function or biophoton emission.
- `telomere_proxy` is a **7-SNP genotype-derived risk score** (Codd 2013, Mangino 2009), not measured telomere length. The actual length depends on cell type, age, lifestyle, and is roughly 30–40% heritable.
- `cpg_promoter_density` is, per §8.7.a correction, primarily a **chip-coverage-consistency proxy**, not personal CpG-island content.

These are scaffolding for the architecture, not biological measurements. Real measurements require: 23andMe Health+ ($199 with mtDNA heteroplasmy depth), TeloYears or similar ($89–149), Episona/methylation array ($299+).

### 3.3 NOT validation of w_em > 0

R_intra_em is currently computed as a uniform mean of 5 components. We have no evidence that EM-coupled components (w_em > 0) explain variance beyond a null model where they are weighted at zero. Phase B exists specifically to test this.

### 3.4 NOT validation of URB #826 §5.1/§5.2/§5.3 differentiated predictions

URB #826's actual hypothesis content lives in the differentiated predictions:
- §5.1: MZ twins should show higher R_intra coherence than DZ twins (need twin pairs)
- §5.2: Cancer-survivor cohort should show shifted R_intra distribution (need cohort)
- §5.3: Meditation-trained subjects should show modulable R_intra response (need N≥10 subjects)

We are at N=1, no twin, no longitudinal modulation protocol. None of §5.1–§5.3 is testable today.

### 3.5 NOT a test against a strong null

Architecturally, dev = 4.8488 vs §8.6 dev = 4.9285 is a 0.0797 shift in the predicted direction. But under a uniform-weights null hypothesis, the simulator produces **whatever R_intra_em says it should** — there is no surprise here. To get a real test, we'd need to randomly permute Brandon's component values and verify dev increases. We did not run that null in this session.

---

## 4. Bayesian translation, calibrated

| Question | Posterior shift |
|---|---|
| "Is the simulator implemented correctly?" | ↑ moderate (4-decimal reproduction is meaningful) |
| "Is the 23andMe haploid parser bug-free?" | ↑ strong (live verification at N=1) |
| "Is R_intra_em a useful descriptor of subject state?" | ↑ small (deterministic propagation, not empirical signal) |
| "Is URB #826 (biophoton/EM-DNA carrier) true?" | **0 (no shift)** |
| "Are biophotons mediating I-Cell coherence?" | **0 (no shift)** |
| "Should Brandon spend $89–199 on real telomere/methylation assays?" | depends on Phase B w_em result |

This is the most important calibration of the day. The §10.4 success is real engineering progress; it is not evidence for the hypothesis.

---

## 5. What unlocks at Phase B

Phase B (weight learning) requires three things, in order:

1. **Multi-time-point data** per subject → we have this from Oura (30+ days)
2. **A daytime-HRV stream** to break the substitution → Polar H10 unblocks this
3. **A target outcome** to learn against → Oura readiness score (next-day) is the natural target at $0

With these three, Phase B fits:

```
target_score(t+1) ≈ f(R_intra_em(t)) = sigmoid(Σ_i w_i × component_i(t))
```

…where target_score is next-day Oura readiness (or sleep score, or HRV trend), components are the 5 (or 6 with daytime HRV) R_intra components, and weights are constrained to sum to 1 with all w_i ≥ 0.

**Falsification criterion for Phase B (proposed for pre-registration in §10.5):**
- If learned w_em (genome-derived components: mito + telomere + cpg) sum to **less than 0.10**, and HRV components (overnight + daytime) sum to > 0.85, then URB #826's claim that EM-coupled DNA components add explanatory variance is **falsified at this subject**.
- If w_em components sum to **> 0.30**, URB #826 claim is **partially supported** (but not confirmed; need cross-subject replication for confirmation).
- Anything in between is inconclusive.

---

## 6. Forward path summary

| Step | Cost | Time | Status |
|---|---|---|---|
| Phase H-1 PARTIAL (§8.6) | $0 | done | ✅ 2026-04-30 |
| Phase H-1 FULL-4-of-5 (§8.7) | $0 | done | ✅ 2026-05-01 morning |
| Oura 30-day full harvest (T003) | $0 | today | building |
| PPG biophoton-signature proxy (T004) | $0 | today | building |
| Phase B scaffold (T005) | $0 | today | building |
| Phase B §10.5 pre-registration | $0 | today | pending |
| Polar H10 unblock (T002 procedure) | ~$80–90 | when Brandon orders | procedure ready |
| Phase B §8.8 outcome | $0 after H10 | tomorrow | pending |
| URB #826 §5.1–§5.3 differentiated predictions | $$$+ | TBD | blocked by N=1 |

---

## 7. Honest one-liner

**dev=4.8488 ✅ confirms our math; it does not confirm Brandon's biophoton hypothesis. Phase B is the test that matters.**
